Cantor Fitzgerald says buy Catamaran aggressively on Q1 selloff

 

Cantor Fitzgerald analyst Tom Liston says that he views the fact that there was no further disclosure on the Cigna contract as positive, and now believes there is “an overwhelming probability” that the contract will stay with Catamaran for at least one more year.

Cantor Fitzgerald analyst Tom Liston says the market is overreacting to Catamaran’s (Catamaran Stock Quote, Chart, News: TSX:CCT) Q1 numbers.

This morning, the company released its Q1, 2013 results. Catamaran earned $56.78-million on revenue of to $3.2-billion, an 88% bump over the $1.7-billion the company posted in the first quarter of 2012.

While the stock was down immediately after the release, Catamaran CEO Mark Thierer said he was pleased with the numbers.

“Catamaran is off to a great start in 2013, and we expect to continue to deliver strong results for the remainder of the year and continued growth going forward,” he said.

Cantor Fitzgerald analyst Tom Liston says Catamaran shares are overreacting to a slight revenue and EBITDA miss. Noting that the company did beat the street’s expectation on EPS, he says there are several positive catalysts for the company over the next few months, and he would be an aggressive buyer of the stock on the selloff that followed the Q1 news. In a research update to clients this morning, Liston maintained his BUY recommendation and $65 one-year target on Catamaran.

In Febraury, shares of Catamaran were hit after speculation that it would not be given the chance to buy Cigna’s pharmacy plans, because that company would keep its PBM business in house rather than sell it. Liston says that he views the fact that there was no further disclosure on the Cigna contract as positive, and now believes there is “an overwhelming probability” that the contract will stay with Catamaran for at least one more year.

Shares of CCT on the TSX closed today down 7.2% to $53.37.

More Cantech Analysts

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cct
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Is Peloton Stock a Buy? (May, 2024)

Following news of a restructuring, Roth MKM analyst George Kelly has chopped his price target on Peloton (Peloton Stock Quote,… [Read More]

9 hours ago

Is Ascend Wellness stock a buy?

Ahead of the company's first quarter results, Beacon analyst Russell Stanley thinks Ascend Wellness (Ascend Wellness Stock Quote, Chart, News,… [Read More]

9 hours ago

Paradigm chops price target on Snipp Interactive

Following the company's fourth quarter results, Paradigm Capital analyst Daniel Rosenberg has cut his price target on Snipp Interactive (Snipp… [Read More]

10 hours ago

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

1 day ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

1 day ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

2 days ago